26 April 2004 14:02
Belarus to Test GenoMed`s Novel Approach to West Nile Virus Encephalitis
ST. LOUIS, April 26 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED), a Next Generation Disease
Management(TM) company that uses its expertise in genomics to improve patient outcomes, said today that the leading
experts in West Nile virus encephalitis in Belarus will collaborate with the Company in treating cases of suspected West
Nile virus encephalitis this summer. Belarus, formerly a part of the USSR, is now an independent, democratic country of
10.5 million people which lies between Poland and Russia; its capital is Minsk.
Researchers from the Research Institute for Epidemiology & Microbiology (RIEM) in Minsk, Belarus, consisting of
Dr. Tamara Samoilova, Head of the Lab of Arboviral Infections, Professor of Immunology Leonid Titov, Director of the
RIEM, and Professor of Neurology Joseph Protas, Head of the Lab of Viral Neuroinfections will test GenoMed's
protocol for viral encephalitis in Belarus this summer. Normally, there are 50,000 patients with fever every year in
Belarus, including 300 cases of viral encephalitis of uncertain cause. Dr. Samoilova has shown that West Nile virus
accounts for a significant fraction of the patients with fever and previously undiagnosed viral encephalitis.
The protocol developed by GenoMed uses drugs currently in use by primary care physicians in every country, available
in every drug store, and already proven to be safe. The Belarusian experts share GenoMed's belief that encephalitis
and death result from an over-response by a person's immune system to the West Nile virus. GenoMed's protocol,
which is patent-pending, gently suppresses the immune system, thus potentially saving the patient from paralysis or
death.
GenoMed's treatment has a 100% cure rate so far among immunocompetent patients, including the elderly. No human
vaccine yet exists for West Nile virus, nor is any other treatment as inexpensive, safe, or already available like
GenoMed's.
GenoMed is conducting a free clinical trial for West Nile virus this summer in the United States as well as Belarus,
and hopes also to recruit patients from Canada, Israel, Europe, and the Middle East. Patients can enroll by clicking on
the "West Nile Trial" button at http://www.genomedics.com/ .
Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, is a Harvard- and Oxford-educated physician, who trained
for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St.
Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the
field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the
angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr.
Moskowitz's novel approach to viral disease, including West Nile virus encephalitis, avian influenza (bird flu),
and SARS, are regarded as innovative and potentially useful treatments for currently incurable diseases.
About GenoMed
GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. GenoMed is a
Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic
pathways that cause disease. The Company is currently marketing its treatment to prevent kidney failure due to diabetes
and high blood pressure, and to delay emphysema.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s
(the Company's) finances and treatments. The words or phrases "ought to," "should,"
"could," "may," or similar expressions are intended to identify "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ
materially from those projected in the forward looking statements as a result of a number of risks and uncertainties,
including but not limited to: (a) whether our treatment for West Nile virus encephalitis continues to be as effective as
it has been so far; (b) whether sufficient medication is available and affordable in Belarus; (c) whether our server
holds up to international demand; (d) our research and development being subject to other economic, regulatory,
governmental, and technological factors. Statements made herein are as of the date of this press release and should not
be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any
obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement. GenoMed, Inc.
CONTACT: David W. Moskowitz, MD, MA, FACP, of GenoMed, Inc., +1-314-977-0115, dwmoskowitz@genomedics.com , or Paul
Knopick of E & E Communications, +1-949-707-5365, pknopick@eandecommunications.com
Web site: http://www.genomedics.com/
[PR Newswire (US)] |
RUSSIA IN FACTS
